Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)

被引：0
|
作者：
Duan, Heying [1 ]
Girod, Bradley [1 ]
Ninatti, Gaia [1 ]
Ferri, Valentina [1 ]
Kunz, Pamela [2 ]
Fisher, George [3 ]
Moradi, Farshad [1 ]
Davidzon, Guido [4 ]
Franc, Benjamin [1 ]
Iagaru, Andrei [5 ]
Aparici, Carina Mari [1 ]
机构：
[1] Stanford Univ, Div Nucl Med, Radiol, Stanford, CA 94305 USA
[2] Stanford Canc Ctr, Stanford, CA USA
[3] Stanford Univ, Oncol, Stanford, CA 94305 USA
[4] Stanford Univ, Radiol Nucl Med, Stanford, CA 94305 USA
[5] Stanford Univ, Stanford, CA 94305 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1442
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S468 - S469
  • [32] The value of dosimetry in Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors: literature and practical aspects
    Di Dia, Amalia
    Ferrari, Mahila E.
    Travaini, Laura Lavinia
    Grappeja, Lorenza
    Guglielmo, Priscilla
    Barone, Antonio
    Mei, Riccardo
    Papi, Stefano
    Ceci, Francesco
    Grana, Chiara Maria
    CLINICAL AND TRANSLATIONAL IMAGING, 2025, : 121 - 129
  • [33] Peptide receptor radionuclide therapy of neuroendocrine tumors
    Haug, A. R.
    Bartenstein, P.
    ONKOLOGE, 2011, 17 (07): : 602 - +
  • [34] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
    Bodei, Lisa
    Kidd, Mark
    Prasad, Vikas
    Modlin, Irvin M.
    NEUROENDOCRINE TUMORS: A MULTIDISCIPLINARY APPROACH, 2015, 44 : 198 - 215
  • [35] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
    Basu, Sandip
    Parghane, Rahul, V
    Kamaldeep
    Chakrabarty, Sudipta
    SEMINARS IN NUCLEAR MEDICINE, 2020, 50 (05) : 447 - 464
  • [36] Peptide Receptor Radionuclide Therapy (PRRT) a Novel Option as Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors: A Surgical Series
    Miotto, M.
    Nessi, C.
    Cingarlini, S.
    Severi, S.
    Paganelli, G.
    Malleo, G.
    D'Onofrio, M.
    Pea, A.
    Vincenzi, S.
    Scarpa, A.
    Salvia, R.
    Landoni, L.
    NEUROENDOCRINOLOGY, 2019, 108 : 254 - 254
  • [37] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
    Marco Schiavo Lena
    Stefano Partelli
    Paola Castelli
    Valentina Andreasi
    Chanel Elisha Smart
    Eleonora Pisa
    Mirco Bartolomei
    Emilio Bertani
    Giuseppe Zamboni
    Massimo Falconi
    Claudio Doglioni
    Endocrine Pathology, 2020, 31 : 119 - 131
  • [38] Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Metastatic Low Grade Neuroendocrine Tumors (mNETs)
    Naraev, Boris G.
    Sharma, Nancy
    Engelman, Eric S.
    Bushnell, David L., Jr.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur R.
    PANCREAS, 2012, 41 (02) : 347 - 348
  • [39] Real-world analysis of peptide receptor radionuclide therapy (PRRT) in the treatment of neuroendocrine tumors.
    Chau, Justin
    Yu, Nanmeng
    Bakeri, Hirva
    Menda, Yusuf
    Dillon, Joseph S.
    Chandrasekharan, Chandrikha
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Safety in Patients With Neuroendocrine Tumors Receiving Telotristat Ethyl (TE) With Peptide Receptor Radionuclide Therapy (PRRT)
    Chauhan, A.
    Binder, P.
    Tesfaye, E.
    Seth, K.
    Lapuerta, P.
    PANCREAS, 2021, 50 (03) : 447 - 448
12345